Tradestie Institutional Equity Comparison Engine

KPRX vs NMAD โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

KPRX Overall Edge

KPRX Captures Institutional Edge (3โ€“0 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Kiora Pharmaceuticals, Inc. Common Stock (KPRX) driven by superior Valuation, Growth & Margin, Momentum & Technical. Fundamentally, KPRX trades at 1.7x Forward P/E with -890.2% operating margin (+0.0% YoY revenue) versus NMAD at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, KPRX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against NMAD sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner KPRX
KPRX 1.7x vs NMAD N/M Fwd P/E
Growth & Margin Winner KPRX
Op Margin -890.2% vs N/A ยท YoY +0.0% vs N/A
Momentum & Technical Winner KPRX
1Y -62.5% vs -65.1% ยท 52W Pos 0% vs 8%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
KPRX NASDAQ
Kiora Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$0.72
-12.28% 1D
Market Cap $3.6M
1M Return -68.96%
1Y Return -62.49%
Forward P/E 1.7x
Unified AI Score
47.5 / 100 HOLD
Tech 45.0 Fund 46.0 Flow 50.0 Mom 55.0
NMAD US Equity
NMAD
Institutional Equity
$2.56
+13.53% 1D
Market Cap N/A
1M Return -28.89%
1Y Return -65.12%
Forward P/E N/M
Unified AI Score
47.9 / 100 HOLD
Tech 43.0 Fund 49.0 Flow 50.0 Mom 70.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: KPRX -62.49% NMAD -65.12% Spread: +6.64 pp (NMAD Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
KPRX TTM Op. Margin: -890.2% NMAD TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on KPRX vs NMAD. Trailing 12-month operating profitability (KPRX -890.2% vs NMAD N/A) and valuation multiples (KPRX 1.7x vs NMAD N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: KPRX (8) vs NMAD (2)
Institutional Metric KPRX NMAD Criterion Row Winner
Market Capitalization Scale $3.6M N/A Larger Scale KPRX
Trailing P/E Ratio Valuation 1.7x N/M Lower Multiple KPRX
Forward P/E Ratio Valuation 1.7x N/M Lower Multiple KPRX
Revenue Growth (YoY) Growth +0.0% N/A Higher Growth KPRX
Operating Margin (TTM) Profitability -890.2% N/A Higher Margin KPRX
Net Profit Margin Profitability 0.0% N/A Higher Margin KPRX
Return on Equity (ROE) Capital Efficiency -67.7% N/A Higher ROE KPRX
52-Week Range Position Momentum 0% ($1โ€“$3) 8% ($2โ€“$8) Stronger Trend NMAD
Beta / 30D Volatility Risk Regime 1.62ฮฒ ยท 126% Vol 0.52ฮฒ ยท 173% Vol Lower Realized Risk KPRX
Unified Institutional Score Composite Signal 47.5 / 100 (HOLD) 47.9 / 100 (HOLD) Higher Composite NMAD

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full KPRX vs NMAD Buy Guide
KPRX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live KPRX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
NMAD UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live NMAD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither KPRX nor NMAD registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.